1
|
Griffiths MR, Pattison DA, Latter M, Kuan K, Taylor S, Tieu W, Kryza T, Meyrick D, Lee BQ, Hansen A, Rose SE, Puttick SG. First-in-Human 212Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2024; 65:664. [PMID: 38423783 PMCID: PMC10995529 DOI: 10.2967/jnumed.123.267189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/23/2024] [Indexed: 03/02/2024] Open
Affiliation(s)
- Matthew R Griffiths
- Department of Nuclear Medicine and Specialist PET Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - David A Pattison
- Department of Nuclear Medicine and Specialist PET Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - Melissa Latter
- Department of Nuclear Medicine and Specialist PET Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - Kevin Kuan
- AdvanCell, Sydney, New South Wales, Australia; and
| | | | - William Tieu
- AdvanCell, Sydney, New South Wales, Australia; and
| | - Thomas Kryza
- AdvanCell, Sydney, New South Wales, Australia; and
| | | | | | - Aaron Hansen
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | | | | |
Collapse
|
2
|
Shah ET, Molloy C, Gough M, Kryza T, Samuel SG, Tucker A, Bhatia M, Ferguson G, Heyman R, Vora S, Monkman J, Bolderson E, Kulasinghe A, He Y, Gabrielli B, Hooper JD, Richard DJ, O'Byrne KJ, Adams MN. Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. Br J Cancer 2024; 130:1196-1205. [PMID: 38287178 PMCID: PMC10991355 DOI: 10.1038/s41416-024-02584-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 12/18/2023] [Accepted: 01/11/2024] [Indexed: 01/31/2024] Open
Abstract
BACKGROUND 5-Fluorouracil (5-FU) remains a core component of systemic therapy for colorectal cancer (CRC). However, response rates remain low, and development of therapy resistance is a primary issue. Combinatorial strategies employing a second agent to augment the therapeutic effect of chemotherapy is predicted to reduce the incidence of treatment resistance and increase the durability of response to therapy. METHODS Here, we employed quantitative proteomics approaches to identify novel druggable proteins and molecular pathways that are deregulated in response to 5-FU, which might serve as targets to improve sensitivity to chemotherapy. Drug combinations were evaluated using 2D and 3D CRC cell line models and an ex vivo culture model of a patient-derived tumour. RESULTS Quantitative proteomics identified upregulation of the mitosis-associated protein Aurora B (AURKB), within a network of upregulated proteins, in response to a 24 h 5-FU treatment. In CRC cell lines, AURKB inhibition with the dihydrogen phosphate prodrug AZD1152, markedly improved the potency of 5-FU in 2D and 3D in vitro CRC models. Sequential treatment with 5-FU then AZD1152 also enhanced the response of a patient-derived CRC cells to 5-FU in ex vivo cultures. CONCLUSIONS AURKB inhibition may be a rational approach to augment the effectiveness of 5-FU chemotherapy in CRC.
Collapse
Affiliation(s)
- Esha T Shah
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Christopher Molloy
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Madeline Gough
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Thomas Kryza
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Selwin G Samuel
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Amos Tucker
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Maneet Bhatia
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Genevieve Ferguson
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Rebecca Heyman
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Shivam Vora
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - James Monkman
- Frazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Emma Bolderson
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Arutha Kulasinghe
- Frazer Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Yaowu He
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Brian Gabrielli
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - John D Hooper
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Derek J Richard
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
| | - Kenneth J O'Byrne
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia
- Cancer Services, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD, 4102, Australia
| | - Mark N Adams
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
| |
Collapse
|
3
|
Janaththani P, Tevz G, Fernando A, Malik A, Rockstroh A, Kryza T, Walpole C, Moya L, Lehman M, Nelson C, Srinivasan S, Clements J, Batra J. Unravelling the Role of Iroquois Homeobox 4 and its Interplay with Androgen Receptor in Prostate Cancer. Res Sq 2023:rs.3.rs-3295914. [PMID: 38076926 PMCID: PMC10705702 DOI: 10.21203/rs.3.rs-3295914/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/11/2024]
Abstract
Genome-wide association studies have linked Iroquois-Homeobox 4 (IRX4) as a robust expression quantitative-trait locus associated with prostate cancer (PCa) risk. However, the intricate mechanism and regulatory factors governing IRX4 expression in PCa remain poorly understood. Here, we unveil enrichment of androgen-responsive gene signatures in metastatic prostate tumors exhibiting heightened IRX4 expression. Furthermore, we uncover a novel interaction between IRX4 and the androgen receptor (AR) co-factor, FOXA1, suggesting that IRX4 modulates PCa cell behavior through AR cistrome alteration. Remarkably, we identified a distinctive short insertion-deletion polymorphism (INDEL), upstream of the IRX4 gene that differentially regulates IRX4 expression through the disruption of AR binding. This INDEL emerges as the most significant PCa risk-associated variant within the 5p15 locus, in a genetic analysis involving 82,591 PCa cases and 61,213 controls and was associated with PCa survival in patients undergoing androgen-deprivation therapy. These studies suggest the potential of this INDEL as a prognostic biomarker for androgen therapy in PCa and IRX4 as a potential therapeutic target in combination with current clinical management.
Collapse
Affiliation(s)
- Panchadsaram Janaththani
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne, Victoria
| | - Gregor Tevz
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Achala Fernando
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Adil Malik
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Anja Rockstroh
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Thomas Kryza
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Mater Research UQ, Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Carina Walpole
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Mater Research UQ, Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Leire Moya
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Melanie Lehman
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Canada
| | - Colleen Nelson
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - The Australian Prostate Cancer BioResource
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | | | - Srilakshmi Srinivasan
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Judith Clements
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
| | - Jyotsna Batra
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Translational Research Institute, Woolloongabba, Brisbane, Queensland, Australia
- Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, Queensland, Australia
| |
Collapse
|
4
|
Gough M, Liu C, Srinivasan B, Wilkinson L, Dunk L, Yang Y, Schreiber V, Tuffaha H, Kryza T, Hooper JD, Lakhani SR, Snell CE. Improved concordance of challenging human epidermal growth factor receptor 2 dual in-situ hybridisation cases with the use of a digital image analysis algorithm in breast cancer. Histopathology 2023; 83:647-656. [PMID: 37366040 DOI: 10.1111/his.15000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/09/2023] [Accepted: 06/12/2023] [Indexed: 06/28/2023]
Abstract
AIMS Accurate assessment of human epidermal growth factor receptor 2 (HER2) expression by HER2 immunohistochemistry and in-situ hybridisation (ISH) is critical for the management of patients with breast cancer. The revised 2018 ASCO/CAP guidelines define 5 groups based on HER2 expression and copy number. Manual pathologist quantification by light microscopy of equivocal and less common HER2 ISH groups (groups 2-4) can be challenging, and there are no data on interobserver variability in reporting of these cases. We sought to determine whether a digital algorithm could improve interobserver variability in the assessment of difficult HER2 ISH cases. METHODS AND RESULTS HER2 ISH was evaluated in a cohort enriched for less common HER2 patterns using standard light microscopy versus analysis of whole slide images using the Roche uPath HER2 dual ISH image analysis algorithm. Standard microscopy demonstrated significant interobserver variability with a Fleiss's kappa value of 0.471 (fair-moderate agreement) improving to 0.666 (moderate-good) with the use of the algorithm. For HER2 group designation (groups 1-5), there was poor-moderate reliability between pathologists by microscopy [intraclass correlation coefficient (ICC) = 0.526], improving to moderate-good agreement (ICC = 0.763) with the use of the algorithm. In subgroup analysis, the algorithm improved concordance particularly in groups 2, 4 and 5. Time to enumerate cases was also significantly reduced. CONCLUSION This work demonstrates the potential of a digital image analysis algorithm to improve the concordance of pathologist HER2 amplification status reporting in less common HER2 groups. This has the potential to improve therapy selection and outcomes for patients with HER2-low and borderline HER2-amplified breast cancers.
Collapse
Affiliation(s)
- Madeline Gough
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
| | - Cheng Liu
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
- Faculty of Medicine, The University of Queensland, Herston, Australia
| | - Bhuvana Srinivasan
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
| | - Lisa Wilkinson
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
| | - Louisa Dunk
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
| | - Yuanhao Yang
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
| | - Veronika Schreiber
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
| | - Haitham Tuffaha
- Centre for the Business and Economics of Health, The University of Queensland, St Lucia, Australia
| | - Thomas Kryza
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
| | - John D Hooper
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
| | - Sunil R Lakhani
- Centre for Clinical Research, The University of Queensland, Herston, Australia
- Pathology Queensland, The Royal Brisbane Women's Hospital, Herston, Australia
| | - Cameron E Snell
- Mater Pathology, Duncombe Building, Raymond Terrace, South Brisbane, Australia
- Mater Research Institute, Translational Research Institute, Woolloongabba, Australia
- Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
| |
Collapse
|
5
|
McGuckin MA, Davies JM, Felgner P, Wong KY, Giri R, He Y, Moniruzzaman M, Kryza T, Sajiir H, Hooper JD, Florin TH, Begun J, Oussalah A, Hasnain SZ, Hensel M, Sheng YH. MUC13 Cell Surface Mucin Limits Salmonella Typhimurium Infection by Protecting the Mucosal Epithelial Barrier. Cell Mol Gastroenterol Hepatol 2023; 16:985-1009. [PMID: 37660948 PMCID: PMC10630632 DOI: 10.1016/j.jcmgh.2023.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 08/25/2023] [Accepted: 08/28/2023] [Indexed: 09/05/2023]
Abstract
BACKGROUND & AIMS MUC13 cell surface mucin is highly expressed on the mucosal surface throughout the intestine, yet its role against bacterial infection is unknown. We investigated how MUC13 impacts Salmonella typhimurium (S Tm) infection and elucidated its mechanisms of action. METHODS Muc13-/- and wild-type littermate mice were gavaged with 2 isogenic strains of S Tm after pre-conditioning with streptomycin. We assessed clinical parameters, cecal histology, local and systemic bacterial load, and proinflammatory cytokines after infection. Cecal enteroids and epithelial cell lines were used to evaluate the mechanism of MUC13 activity after infection. The interaction between bacterial SiiE and MUC13 was assessed by using siiE-deficient Salmonella. RESULTS S Tm-infected Muc13-/- mice had increased disease activity, histologic damage, and higher local and systemic bacterial loads. Mechanistically, we found that S Tm binds to MUC13 through its giant SiiE adhesin and that MUC13 acts as a pathogen-binding decoy shed from the epithelial cell surface after pathogen engagement, limiting bacterial invasion. In addition, MUC13 reduces epithelial cell death and intestinal barrier breakdown by enhancing nuclear factor kappa B signaling during infection, independent of its decoy function. CONCLUSIONS We show for the first time that MUC13 plays a critical role in antimicrobial defense against pathogenic S Tm at the intestinal mucosal surface by both acting as a releasable decoy limiting bacterial invasion and reducing pathogen-induced cell death. This further implicates the cell surface mucin family in mucosal defense from bacterial infection.
Collapse
Affiliation(s)
- Michael A McGuckin
- Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; Faculty of Medicine Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria, Australia.
| | - Julie M Davies
- Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Pascal Felgner
- CellNanOs, Center for Cellular Nanoanalytics, Osnabrueck, Germany; Division Microbiology, Universitaet Osnabrueck, Osnabrueck, Germany
| | - Kuan Yau Wong
- Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Rabina Giri
- Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Yaowu He
- Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia
| | - Md Moniruzzaman
- Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, Australia
| | - Thomas Kryza
- Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia
| | - Haressh Sajiir
- Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - John D Hooper
- Cancer Biology Group, Mater Research Institute-University of Queensland, Woolloongabba, Queensland, Australia
| | - Timothy H Florin
- Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Jakob Begun
- Inflammatory Bowel Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Abderrahim Oussalah
- Department of Molecular Medicine, Division of Biochemistry, Molecular Biology, Nutrition, and Metabolism, University Hospital of Nancy, Nancy, France; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, Nancy, France; Reference Center for Inborn Errors of Metabolism (ORPHA67872), University Hospital of Nancy, Nancy, France
| | - Sumaira Z Hasnain
- Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Michael Hensel
- CellNanOs, Center for Cellular Nanoanalytics, Osnabrueck, Germany; Division Microbiology, Universitaet Osnabrueck, Osnabrueck, Germany
| | - Yong H Sheng
- Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia; Laboratory of B-Lymphocytes in Autoimmunity and Malignancies, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
| |
Collapse
|
6
|
Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Panchadsaram J, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Gago-Dominguez M, Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Key TJ, Haiman CA, Giles GG, Vega A, Wiklund F, Neal DE, Kogevinas M, Stampfer MJ, Nordestgaard BG, Brenner H, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R, Clements J, Batra J. Biochemical activity induced by a germline variation in KLK3 (PSA) associates with cellular function and clinical outcome in prostate cancer. Res Sq 2023:rs.3.rs-2650312. [PMID: 37034758 PMCID: PMC10081352 DOI: 10.21203/rs.3.rs-2650312/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Genetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility. The non-synonymous KLK3 SNP, rs17632542 (c.536T>C; Ile163Thr-substitution in PSA) is associated with reduced prostate cancer risk, however, the functional relevance is unknown. Here, we identify that the SNP variant-induced change in PSA biochemical activity as a previously undescribed function mediating prostate cancer pathogenesis. The 'Thr' PSA variant led to small subcutaneous tumours, supporting reduced prostate cancer risk. However, 'Thr' PSA also displayed higher metastatic potential with pronounced osteolytic activity in an experimental metastasis in-vivo model. Biochemical characterization of this PSA variant demonstrated markedly reduced proteolytic activity that correlated with differences in in-vivo tumour burden. The SNP is associated with increased risk for aggressive disease and prostate cancer-specific mortality in three independent cohorts, highlighting its critical function in mediating metastasis. Carriers of this SNP allele had reduced serum total PSA and a higher free/total PSA ratio that could contribute to late biopsy decisions and delay in diagnosis. Our results provide a molecular explanation for the prominent 19q13.3 KLK locus, rs17632542 SNP, association with a spectrum of prostate cancer clinical outcomes.
Collapse
Affiliation(s)
- Srilakshmi Srinivasan
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Thomas Kryza
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia
| | - Nathalie Bock
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Brian WC Tse
- Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia
| | - Kamil A. Sokolowski
- Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia
| | - Janaththani Panchadsaram
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Leire Moya
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Carson Stephens
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Ying Dong
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
| | - Joan Röhl
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
| | - Saeid Alinezhad
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Ian Vela
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Department of Urology, Princess Alexandra Hospital, Brisbane, Woolloongabba, Brisbane, QLD, Australia
| | - Joanna L. Perry-Keene
- Pathology Queensland, Sunshine Coast University Hospital Laboratory, Birtinya, Sunshine Coast, QLD, Australia
| | - Katie Buzacott
- Pathology Queensland, Sunshine Coast University Hospital Laboratory, Birtinya, Sunshine Coast, QLD, Australia
| | - The IMPACT Study
- The Institute of Cancer Research, London, SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, London, UK
| | - Manuela Gago-Dominguez
- Genomic Medicine Group, Galician Foundation of Genomic Medicine, IDIS, Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - The PROFILE Study Steering Committee
- The Institute of Cancer Research, London, SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, London, UK
- Ronald and Rita McAulay Foundation, London, UK
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- University of Oxford, Oxford, UK
- Queen Mary University of London, London, UK
| | - Johanna Schleutker
- Institute of Biomedicine, Kiinamyllynkatu 10, FI-20014 University of Turku, Finland
- Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland
| | - Christiane Maier
- Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany
| | - Kenneth Muir
- Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, M13 9PL, UK
- Warwick Medical School, University of Warwick, Coventry, UK
| | - Catherine M. Tangen
- SWOG Statistical Center, Division of Public Health Sciences
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Nora Pashayan
- Department of Applied Health Research, University College London, London, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, USA
| | - Alicja Wolk
- Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Janet L. Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, USA
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, USA
| | - Lorelei A. Mucci
- Department of Epidemiology,Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
| | - Stella Koutros
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, USA
| | - Olivier Cussenot
- CeRePP and Sorbonne Universite, GRC N°5 AP-HP, Tenon Hospital, Paris, France
| | - Karina Dalsgaard Sorensen
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark
- Department of Clinical Medicine, Aarhus University & Department of Molecular Medicine (MOMA), Aarhus University Hospital, DK-8200 Aarhus N., Denmark
| | | | - Timothy J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Christopher A. Haiman
- Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, USA
| | - Graham G. Giles
- Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Ana Vega
- Fundación Pública Galega de Medicina Xenómica-SERGAS, Instituto de Investigación Sanitaria (IDIS), Santiago de Compostela, Spain
- Biomedical Network on Rare Diseases (CIBERER), Santiago de Compostela, Spain
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - David E. Neal
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, England
- Department of Oncology, Addenbrooke’s Hospital, University of Cambridge, England
| | - Manolis Kogevinas
- ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- IMIM (Hospital del Mar Research Institute), Barcelona, Spain
- Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Meir J. Stampfer
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
| | - Børge G. Nordestgaard
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
- The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marija Gamulin
- Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Frank Claessens
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Belgium
| | - Olle Melander
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Anders Dahlin
- Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
| | - Pär Stattin
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Göran Hallmans
- Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden
| | - Christel Häggström
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
- Department of Biobank Research, Umeå University, Umeå, Sweden
| | | | - Elin Thysell
- Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
| | - Ann-Charlotte Rönn
- Clinical Research Center, Karolinska University Hospital, Huddinge, Sweden
| | - Weiqiang Li
- Icahn Institute for Data Science and Genome Technology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Nigel Brown
- Department of Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia
| | - Goce Dimeski
- Department of Chemical Pathology, Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia
| | - Benjamin Shepherd
- Department of Anatomical Pathology, Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Brisbane, QLD, Australia
| | - Tokhir Dadaev
- The Institute of Cancer Research, London, SM2 5NG, UK
| | - Mark N. Brook
- The Institute of Cancer Research, London, SM2 5NG, UK
| | - Amanda B. Spurdle
- Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD, Australia
| | - Ulf-Håkan Stenman
- Department of Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Hannu Koistinen
- Department of Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, London, SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, London, UK
| | - Robert J. Klein
- Icahn Institute for Data Science and Genome Technology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Hans Lilja
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, England
- Departments of Laboratory Medicine, Surgery (Urology Service) and Medicine (Genitourinary Oncology), Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Rupert C. Ecker
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
- TissueGnostics GmbH, Vienna, Austria
| | - Rosalind Eeles
- The Institute of Cancer Research, London, SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, London, UK
| | | | - The Australian Prostate Cancer BioResource
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Judith Clements
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
| | - Jyotsna Batra
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology (QUT)
- Translational Research Institute, Queensland University of Technology, Woolloongabba, Brisbane, Queensland (QLD), Australia
- Centre for Genomic and Personalised Health, Queensland University of Technology, Brisbane, QLD
| |
Collapse
|
7
|
Gough M, Khan T, Kwah K, He Y, Ratnayake G, Pyke C, Snell C, Hooper J, Kryza T. Abstract P4-07-26: Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancer. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p4-07-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Introduction: CUB-domain containing- protein 1 (CDCP1) is a transmembrane receptor involved in the progression of several cancers. Recent studies demonstrate that CDCP1 is a rational target for the development of innovative targeted therapies for cancer including theranostics agents and antibody-drug conjugates. Objective/Methods: To determine the therapeutic potential of CDCP1 in breast cancer, we investigated its expression in multiple cohorts of breast cancer tissues by immunohistochemistry, as well as in various preclinical models including cell lines, primary cells and patient-derived xenografts using flow cytometry, western blot and immunofluorescence staining. Then, we evaluated the capacity of the CDCP1-targeting chimeric antibody ch10D7 to specifically accumulate in breast cancer lesions in in vivo preclinical models including patient-derived xenografts and breast cancer metastasis models. Finally, we determined the efficacy of the ch10D7-MMAE antibody-drug conjugate to kill breast cancer cells in vitro and breast tumours ex-vivo and in vivo. Results: The CDCP1 receptor is expressed at targetable level in a significant proportion of breast cancer cases with high/intermediate expression detected in ~30% of localized ER-positive cases, ~50% of metastatic ER-positive cases and >70% of Triple negative or HER2-positive cases. Similar proportion of expression was detected in cellular models. We demonstrated that ch10D7 antibody labelled with the radionucleotide Zircodium-89 specifically accumulates in breast cancer lesions in vivo allowing the detection of mammary-fat pad implanted patient-derived xenografts and of breast cancer metastasis by PET/CT imaging. Finally, we confirmed that the ch10D7-MMAE antibody-drug conjugate is very efficient at inducing cell death in vitro as well as controlling primary tumour and metastatic tumour burden in pre-clinical models, conferring a significant survival advantage compared to classical therapy. Conclusion: Our work demonstrates that CDCP1 is a potential target to detect and limit the progression of breast tumours and that biomolecules specifically recognising this receptor are promising agents which could improve survival of patients.
Citation Format: Madeline Gough, Tashbib Khan, Kayden Kwah, Yaowu He, Gishan Ratnayake, Christopher Pyke, Cameron Snell, John Hooper, Thomas Kryza. Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-26.
Collapse
|
8
|
Lyons N, Giri R, Begun J, Clark DA, Proud D, He Y, Hooper J, Kryza T. Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxid Redox Signal 2023. [PMID: 36792932 DOI: 10.1089/ars.2022.0127] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Significance Reactive oxygen species (ROS) are critical to normal cellular function with redox homeostasis achieved by balancing ROS production with removal through detoxification mechanisms. Many of the conventional chemotherapies used to treat colorectal cancer (CRC) derive a proportion of their cytotoxicity from ROS generation and resistance to chemotherapy is associated with elevated detoxification mechanisms. Furthermore, cancer stem cells demonstrate elevated detoxification mechanisms making definitive treatment with existing chemotherapy challenging. In this article we review the roles of ROS in normal and malignant colonic cell biology and how existing and emerging therapies might harness ROS for therapeutic benefit. Recent advances Recent publications have elucidated the contribution of ROS to the cytotoxicity of conventional chemotherapy alongside the emerging approaches of photodynamic therapy (PDT), sonodynamic therapy (SDT) and radiodynamic therapy (RDT) in which ROS are generated in response to excitatory light, sound or X-ray stimuli to promote cancer cell apoptosis. Critical issues The majority of patients with metastatic CRC have a very poor prognosis with 5-year survival of approximately 13% making the need for new or more effective treatments an imperative. Future Directions Modulation of ROS through a combination of new and emerging therapies may improve the efficacy of current chemotherapy providing novel approaches to treat otherwise resistant disease.
Collapse
Affiliation(s)
- Nicholas Lyons
- The University of Queensland, 1974, Mater Research, Woolloongabba, Queensland, Australia;
| | - Rabina Giri
- The University of Queensland, 1974, Mater Research, Woolloongabba, Queensland, Australia;
| | - Jakob Begun
- The University of Queensland, 1974, Mater Research, Woolloongabba, Queensland, Australia;
| | - David A Clark
- Royal Brisbane and Women's Hospital, 3883, Surgery, Herston, Queensland, Australia;
| | - David Proud
- Austin Hospital, 96043, Surgery, Heidelberg, Victoria, Australia;
| | - Yaowu He
- The University of Queensland, 1974, Mater Research, Woolloongabba, Queensland, Australia;
| | - John Hooper
- The University of Queensland, 1974, Mater Research, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, Australia, 4102;
| | - Thomas Kryza
- The University of Queensland, 1974, Mater Research, Woolloongabba, Queensland, Australia;
| |
Collapse
|
9
|
Bock N, Forouz F, Hipwood L, Clegg J, Jeffery P, Gough M, van Wyngaard T, Pyke C, Adams MN, Bray LJ, Croft L, Thompson EW, Kryza T, Meinert C. GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids. Pharmaceutics 2023; 15:pharmaceutics15010261. [PMID: 36678890 PMCID: PMC9867511 DOI: 10.3390/pharmaceutics15010261] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 12/18/2022] [Accepted: 12/21/2022] [Indexed: 01/13/2023] Open
Abstract
3D organoid model technologies have led to the development of innovative tools for cancer precision medicine. Yet, the gold standard culture system (Matrigel®) lacks the ability for extensive biophysical manipulation needed to model various cancer microenvironments and has inherent batch-to-batch variability. Tunable hydrogel matrices provide enhanced capability for drug testing in breast cancer (BCa), by better mimicking key physicochemical characteristics of this disease’s extracellular matrix. Here, we encapsulated patient-derived breast cancer cells in bioprinted polyethylene glycol-derived hydrogels (PEG), functionalized with adhesion peptides (RGD, GFOGER and DYIGSR) and gelatin-derived hydrogels (gelatin methacryloyl; GelMA and thiolated-gelatin crosslinked with PEG-4MAL; GelSH). Within ranges of BCa stiffnesses (1−6 kPa), GelMA, GelSH and PEG-based hydrogels successfully supported the growth and organoid formation of HR+,−/HER2+,− primary cancer cells for at least 2−3 weeks, with superior organoid formation within the GelSH biomaterial (up to 268% growth after 15 days). BCa organoids responded to doxorubicin, EP31670 and paclitaxel treatments with increased IC50 concentrations on organoids compared to 2D cultures, and highest IC50 for organoids in GelSH. Cell viability after doxorubicin treatment (1 µM) remained >2-fold higher in the 3D gels compared to 2D and doxorubicin/paclitaxel (both 5 µM) were ~2.75−3-fold less potent in GelSH compared to PEG hydrogels. The data demonstrate the potential of hydrogel matrices as easy-to-use and effective preclinical tools for therapy assessment in patient-derived breast cancer organoids.
Collapse
Affiliation(s)
- Nathalie Bock
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Max Planck Queensland Centre, Brisbane, QLD 4059, Australia
- Centre for Biomedical Technologies, QUT, Brisbane, QLD 4059, Australia
- Australian Prostate Cancer Research Centre (APCRC-Q), QUT, Brisbane, QLD 4102, Australia
- Correspondence:
| | - Farzaneh Forouz
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Australian Prostate Cancer Research Centre (APCRC-Q), QUT, Brisbane, QLD 4102, Australia
| | - Luke Hipwood
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Centre for Biomedical Technologies, QUT, Brisbane, QLD 4059, Australia
- Gelomics Pty Ltd., Brisbane, QLD 4059, Australia
| | - Julien Clegg
- Centre for Biomedical Technologies, QUT, Brisbane, QLD 4059, Australia
- Gelomics Pty Ltd., Brisbane, QLD 4059, Australia
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
- ARC Training Centre for Cell and Tissue Engineering Technologies, QUT, Brisbane, QLD 4059, Australia
- School of Mechanical, Medical and Process Engineering, QUT, Brisbane, QLD 4000, Australia
| | - Penny Jeffery
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
| | | | - Tirsa van Wyngaard
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
- Breast and Endocrine Surgery, Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia
| | | | - Mark N. Adams
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- ARC Training Centre for Cell and Tissue Engineering Technologies, QUT, Brisbane, QLD 4059, Australia
- Centre for Genomics and Personalised Health, Brisbane, QLD 4000, Australia
| | - Laura J. Bray
- Centre for Biomedical Technologies, QUT, Brisbane, QLD 4059, Australia
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
- ARC Training Centre for Cell and Tissue Engineering Technologies, QUT, Brisbane, QLD 4059, Australia
| | - Laura Croft
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
- Centre for Genomics and Personalised Health, Brisbane, QLD 4000, Australia
| | - Erik W. Thompson
- School of Biomedical Sciences, Faculty of Health, Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
- Centre for Personalised Analysis of Cancers (CPAC), Brisbane, QLD 4102, Australia
| | - Thomas Kryza
- Mater Research Institute, Brisbane, QLD 4102, Australia
| | - Christoph Meinert
- Centre for Biomedical Technologies, QUT, Brisbane, QLD 4059, Australia
- Gelomics Pty Ltd., Brisbane, QLD 4059, Australia
| |
Collapse
|
10
|
Gough M, Kwah K, Khan T, He Y, Pyke C, Ratnayake G, Snell C, Hooper J, Kryza T. Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01571-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
11
|
Khan T, Lyons NJ, Gough M, Kwah KKX, Cuda TJ, Snell CE, Tse BW, Sokolowski KA, Pearce LA, Adams TE, Rose SE, Puttick S, Pajic M, Adams MN, He Y, Hooper JD, Kryza T. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Am J Cancer Res 2022; 12:6915-6930. [PMID: 36276654 PMCID: PMC9576610 DOI: 10.7150/thno.78171] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 09/22/2022] [Indexed: 11/26/2022] Open
Abstract
Rationale: An antibody-drug conjugate (ADC) is a targeted therapy consisting of a cytotoxic payload that is linked to an antibody which targets a protein enriched on malignant cells. Multiple ADCs are currently used clinically as anti-cancer agents significantly improving patient survival. Herein, we evaluated the rationale of targeting the cell surface oncoreceptor CUB domain-containing protein 1 (CDCP1) using ADCs and assessed the efficacy of CDCP1-directed ADCs against a range of malignant tumors. Methods: CDCP1 mRNA expression was evaluated using large transcriptomic datasets of normal/tumor samples for 23 types of cancer and 15 other normal organs, and CDCP1 protein expression was examined in 34 normal tissues, >300 samples from six types of cancer, and in 49 cancer cell lines. A recombinant human/mouse chimeric anti-CDCP1 antibody (ch10D7) was labelled with 89Zirconium or monomethyl auristatin E (MMAE) and tested in multiple pre-clinical cancer models including 36 cancer cell lines and three mouse xenograft models. Results: Analysis of CDCP1 expression indicates elevated CDCP1 expression in the majority of the cancers and restricted expression in normal human tissues. Antibody ch10D7 demonstrates a high affinity and specificity for CDCP1 inducing cell signalling via Src accompanied by rapid internalization of ch10D7/CDCP1 complexes in cancer cells.89Zirconium-labelled ch10D7 accumulates in CDCP1 expressing cells enabling detection of pancreatic cancer xenografts in mice by PET imaging. Cytotoxicity of MMAE-labelled ch10D7 against kidney, colorectal, lung, ovarian, pancreatic and prostate cancer cells in vitro, correlates with the level of CDCP1 on the plasma membrane. ch10D7-MMAE displays robust anti-tumor effects against mouse xenograft models of pancreatic, colorectal and ovarian cancer. Conclusion: CDCP1 directed imaging agents will be useful for selecting cancer patients for personalized treatment with cytotoxin-loaded CDCP1 targeting agents including antibody-drug conjugates.
Collapse
Affiliation(s)
- Tashbib Khan
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Nicholas J Lyons
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Madeline Gough
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Kayden K X Kwah
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Tahleesa J Cuda
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Cameron E Snell
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia.,Mater Health Services, South Brisbane, QLD, Australia
| | - Brian W Tse
- Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Kamil A Sokolowski
- Preclinical Imaging Facility, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Lesley A Pearce
- Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia
| | - Timothy E Adams
- Commonwealth Scientific and Industrial Research Organisation Manufacturing, Parkville, VIC, Australia
| | - Stephen E Rose
- Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia
| | - Simon Puttick
- Commonwealth Scientific and Industrial Research Organisation, Herston, QLD, Australia
| | - Marina Pajic
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Faculty of Medicine, St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Mark N Adams
- School of Biomedical Sciences, Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD, Australia
| | - Yaowu He
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - John D Hooper
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| | - Thomas Kryza
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, Australia
| |
Collapse
|
12
|
Lyons N, Hooper J, Clark D, Riddell A, Kryza T. EP-368 Intraoperative identification of colorectal cancer lesions using indocyanine green labelled antibodies in preclinical murine models. Br J Surg 2022. [DOI: 10.1093/bjs/znac245.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Abstract
Aims
The ability to identify cancerous tissue intraoperatively has the potential to allow for real time identification of involved margins, lymph node involvement and extra-colonic deposits. Here we investigate whether antibodies targeting a novel receptor, anonymously referred to as LN1, a frequently over expressed protein in colorectal cancer (CRC), labelled with indocyanine green (ICG) can be used for the intraoperative detection of malignant tissue in preclinical models.
Methods
Representative metastatic CRC models were generated in 20 NSG mice using HCT116 human CRC cells. Mice were treated with either intravenous ICG labelled LN1 antibodies (LN1-ICG) or control treatments (untreated, free ICG or cotreatment unlabelled LN1 blocking antibody + LN1-ICG). Signal intensity of normal and malignant tissue was quantified from near infrared (NIR) endoscopy and IVIS® in-vivo imaging system.
Results
LN1-ICG labelled antibodies was highly effective in identifying cancerous lesions down to 500nm diameter. Quantification of NIR and IVIS images demonstrate significantly greater tumour signal in the LN1-ICG group versus controls (p=0.004 and p=0.001 respectively). Examination of normal organ tissues demonstrated signal in the liver and digestive tract in keeping with hepatobiliary clearance of ICG but nil further off-site accumulation of LN1-ICG. No difference in signal from the liver, small bowel or colon was noted between groups (p>0.05).
Conclusion
LN1-ICG labelled antibodies were highly effective at identifying even small cancerous deposits in murine models. It is highly likely that these effects could be replicated in human procedures which may allow for perioperative identification of extra-colonic deposits, involved tumour margins or lymph node involvement.
Collapse
Affiliation(s)
| | - John Hooper
- Mater Research Institute
- University of Queensland
| | - David Clark
- University of Queensland
- RBWH Colorectal Cancer Research Unit
| | - Andrew Riddell
- University of Queensland
- RBWH Colorectal Cancer Research Institute
| | - Thomas Kryza
- Mater Research Institute
- University of Queensland
| |
Collapse
|
13
|
Abstract
Kallikrein-related peptidases (KLKs) are critical regulators of the tumour microenvironment. KLKs are proteolytic enzymes regulating multiple functions of bioactive molecules including hormones and growth factors, membrane receptors and the extracellular matrix architecture involved in cancer progression and metastasis. Perturbations of the proteolytic cascade generated by these peptidases, and their downstream signalling actions, underlie tumour emergence or blockade of tumour growth. Recent studies have also revealed their role in tumour immune suppression and resistance to cancer therapy. Here, we present an overview of the complex biology of the KLK family and its context-dependent nature in cancer, and discuss the different therapeutic strategies available to potentially target these proteases.
Collapse
Affiliation(s)
- Srilakshmi Srinivasan
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Thomas Kryza
- Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
- Mater Research Institute, The University of Queensland, Woolloongabba, Brisbane, Queensland, Australia
| | - Jyotsna Batra
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
- Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
- Centre for Genomics and Personalised Medicine, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Judith Clements
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.
- Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.
| |
Collapse
|
14
|
He Y, Khan T, Kryza T, Jones ML, Goh JB, Lyons NJ, Pearce LA, Lee MD, Gough M, Rogers R, Davies CM, Gilks CB, Hodgkinson T, Lourie R, Barry SC, Perrin LC, Williams CC, Puttick S, Adams TE, Munro TP, Hooper JD, Chetty N. Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. Mol Pharm 2021; 18:3464-3474. [PMID: 34448393 DOI: 10.1021/acs.molpharmaceut.1c00401] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Optimal cytoreduction for ovarian cancer is often challenging because of aggressive tumor biology and advanced stage. It is a critical issue since the extent of residual disease after surgery is the key predictor of ovarian cancer patient survival. For a limited number of cancers, fluorescence-guided surgery has emerged as an effective aid for tumor delineation and effective cytoreduction. The intravenously administered fluorescent agent, most commonly indocyanine green (ICG), accumulates preferentially in tumors, which are visualized under a fluorescent light source to aid surgery. Insufficient tumor specificity has limited the broad application of these agents in surgical oncology including for ovarian cancer. In this study, we developed a novel tumor-selective fluorescent agent by chemically linking ICG to mouse monoclonal antibody 10D7 that specifically recognizes an ovarian cancer-enriched cell surface receptor, CUB-domain-containing protein 1 (CDCP1). 10D7ICG has high affinity for purified recombinant CDCP1 and CDCP1 that is located on the surface of ovarian cancer cells in vitro and in vivo. Our results show that intravenously administered 10D7ICG accumulates preferentially in ovarian cancer, permitting visualization of xenograft tumors in mice. The data suggest CDCP1 as a rational target for tumor-specific fluorescence-guided surgery for ovarian cancer.
Collapse
Affiliation(s)
- Yaowu He
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | - Tashbib Khan
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | - Thomas Kryza
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | - Martina L Jones
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Justin B Goh
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Nicholas J Lyons
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | | | | | - Madeline Gough
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | - Rebecca Rogers
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia.,Mater Health Services, South Brisbane, QLD 4101, Australia
| | - Claire M Davies
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia.,Mater Health Services, South Brisbane, QLD 4101, Australia
| | - C Blake Gilks
- Department of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC V6T 2B5, Canada
| | | | - Rohan Lourie
- Mater Health Services, South Brisbane, QLD 4101, Australia
| | - Sinead C Barry
- Mater Health Services, South Brisbane, QLD 4101, Australia
| | - Lewis C Perrin
- Mater Health Services, South Brisbane, QLD 4101, Australia
| | | | | | | | - Trent P Munro
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia
| | - John D Hooper
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD 4102, Australia
| | - Naven Chetty
- Mater Health Services, South Brisbane, QLD 4101, Australia
| |
Collapse
|
15
|
Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, Maneiro M, Tanaka RJ, Bevan CL, Clements JA, Tate EW. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. J Am Chem Soc 2021; 143:8911-8924. [PMID: 34085829 PMCID: PMC9282638 DOI: 10.1021/jacs.1c03950] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
![]()
Kallikrein-related
peptidases (KLKs) are a family of secreted serine
proteases, which form a network (the KLK activome) with an important
role in proteolysis and signaling. In prostate cancer (PCa), increased
KLK activity promotes tumor growth and metastasis through multiple
biochemical pathways, and specific quantification and tracking of
changes in the KLK activome could contribute to validation of KLKs
as potential drug targets. Herein we report a technology platform
based on novel activity-based probes (ABPs) and inhibitors enabling
simultaneous orthogonal analysis of KLK2, KLK3, and KLK14 activity
in hormone-responsive PCa cell lines and tumor homogenates. Importantly,
we identifed a significant decoupling of KLK activity and abundance
and suggest that KLK proteolysis should be considered as an additional
parameter, along with the PSA blood test, for accurate PCa diagnosis
and monitoring. Using selective inhibitors and multiplexed fluorescent
activity-based protein profiling (ABPP), we dissect the KLK activome
in PCa cells and show that increased KLK14 activity leads to a migratory
phenotype. Furthermore, using biotinylated ABPs, we show that active
KLK molecules are secreted into the bone microenvironment by PCa cells
following stimulation by osteoblasts suggesting KLK-mediated signaling
mechanisms could contribute to PCa metastasis to bone. Together our
findings show that ABPP is a powerful approach to dissect dysregulation
of the KLK activome as a promising and previously underappreciated
therapeutic target in advanced PCa.
Collapse
Affiliation(s)
- Scott Lovell
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Leran Zhang
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Thomas Kryza
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia.,Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD 4102, Australia
| | - Anna Neodo
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Nathalie Bock
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD 4102, Australia
| | - Elena De Vita
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Elizabeth D Williams
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD 4102, Australia
| | - Elisabeth Engelsberger
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Congyi Xu
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Alexander T Bakker
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Maria Maneiro
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K
| | - Reiko J Tanaka
- Department of Bioengineering, Imperial College London, London SW7 2AZ, U.K
| | - Charlotte L Bevan
- Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, U.K
| | - Judith A Clements
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation and School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD 4102, Australia
| | - Edward W Tate
- Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K.,The Francis Crick Institute, London NW1 1AT, U.K
| |
Collapse
|
16
|
Bock N, Kryza T, Shokoohmand A, Röhl J, Ravichandran A, Wille ML, Nelson CC, Hutmacher DW, Clements JA. In vitro engineering of a bone metastases model allows for study of the effects of antiandrogen therapies in advanced prostate cancer. Sci Adv 2021; 7:7/27/eabg2564. [PMID: 34193425 PMCID: PMC8245033 DOI: 10.1126/sciadv.abg2564] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 05/17/2021] [Indexed: 05/05/2023]
Abstract
While androgen-targeted therapies are routinely used in advanced prostate cancer (PCa), their effect is poorly understood in treating bone metastatic lesions and ultimately results in the development of metastatic castrate resistant prostate cancer (mCRPC). Here, we used an all-human microtissue-engineered model of mineralized metastatic tissue combining human osteoprogenitor cells, 3D printing and prostate cancer cells, to assess the effects of the antiandrogens, bicalutamide, and enzalutamide in this microenvironment. We demonstrate that cancer/bone stroma interactions and antiandrogens drive cancer progression in a mineralized microenvironment. Probing the bone microenvironment with enzalutamide led to stronger cancer cell adaptive responses and osteomimicry than bicalutamide. Enzalutamide presented with better treatment response, in line with enzalutamide delaying time to bone-related events and enzalutamide extending survival in mCRPC. The all-human microtissue-engineered model of mineralized metastatic tissue presented here represents a substantial advance to dissect the role of the bone tumor microenvironment and responses to therapies for mCPRC.
Collapse
Affiliation(s)
- Nathalie Bock
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
- Centre in Regenerative Medicine, IHBI, QUT, Kelvin Grove, 4059 QLD, Australia
- Australian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), QUT, Kelvin Grove, 4059 QLD, Australia
| | - Thomas Kryza
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
| | - Ali Shokoohmand
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
- Centre in Regenerative Medicine, IHBI, QUT, Kelvin Grove, 4059 QLD, Australia
| | - Joan Röhl
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
| | - Akhilandeshwari Ravichandran
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
- Centre in Regenerative Medicine, IHBI, QUT, Kelvin Grove, 4059 QLD, Australia
| | - Marie-Luise Wille
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Australian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), QUT, Kelvin Grove, 4059 QLD, Australia
- Bone and Joint Disorders Program, School of Mechanical Medical, and Process Engineering, Science and Engineering Faculty (SEF), QUT, Brisbane, 4000 QLD, Australia
| | - Colleen C Nelson
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
| | - Dietmar W Hutmacher
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia.
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
- Centre in Regenerative Medicine, IHBI, QUT, Kelvin Grove, 4059 QLD, Australia
- Australian Research Council (ARC) Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), QUT, Kelvin Grove, 4059 QLD, Australia
- Bone and Joint Disorders Program, School of Mechanical Medical, and Process Engineering, Science and Engineering Faculty (SEF), QUT, Brisbane, 4000 QLD, Australia
- ARC Training Centre in Additive Biomanufacturing, QUT, Kelvin Grove, 4059 QLD, Australia
| | - Judith A Clements
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Brisbane 4000, QLD, Australia.
- Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane 4000, QLD, Australia
- Translational Research Institute (TRI), QUT, Woolloongabba, 4102 QLD, Australia
| |
Collapse
|
17
|
Lavergne M, Guillon-Munos A, Lenga Ma Bonda W, Attucci S, Kryza T, Barascu A, Moreau T, Petit-Courty A, Sizaret D, Courty Y, Iochmann S, Reverdiau P. Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. Biol Chem 2021; 402:1257-1268. [PMID: 33977679 DOI: 10.1515/hsz-2020-0389] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 04/30/2021] [Indexed: 11/15/2022]
Abstract
The protease activities are tightly regulated by inhibitors and dysregulation contribute to pathological processes such as cancer and inflammatory disorders. Tissue factor pathway inhibitor 2 (TFPI-2) is a serine proteases inhibitor, that mainly inhibits plasmin. This protease activated matrix metalloproteases (MMPs) and degraded extracellular matrix. Other serine proteases are implicated in these mechanisms like kallikreins (KLKs). In this study, we identified for the first time that TFPI-2 is a potent inhibitor of KLK5 and 12. Computer modeling showed that the first Kunitz domain of TFPI-2 could interact with residues of KLK12 near the catalytic triad. Furthermore, like plasmin, KLK12 was able to activate proMMP-1 and -3, with no effect on proMMP-9. Thus, the inhibition of KLK12 by TFPI-2 greatly reduced the cascade activation of these MMPs and the cleavage of cysteine-rich 61, a matrix signaling protein. Moreover, when TFPI-2 bound to extracellular matrix, its classical localisation, the KLK12 inhibition was retained. Finally, TFPI-2 was downregulated in human non-small-cell lung tumour tissue as compared with non-affected lung tissue. These data suggest that TFPI-2 is a potent inhibitor of KLK12 and could regulate matrix remodeling and cancer progression mediated by KLK12.
Collapse
Affiliation(s)
- Marion Lavergne
- Université de Tours, F-37032Tours, France.,INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France
| | - Audrey Guillon-Munos
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France.,Groupe IMT, Bio3 Institute, 15 rue du Plat D'Etain, F-37020Tours Cedex 1, France
| | - Woodys Lenga Ma Bonda
- Université de Tours, F-37032Tours, France.,INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France
| | - Sylvie Attucci
- Université de Tours, F-37032Tours, France.,INSERM, Imagerie et Cerveau (iBrain), UMR 1253, F-37000Tours, France
| | - Thomas Kryza
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France.,Mater Research Institute, The University of Queensland, Woollongabba Brisbane, QLD, Australia
| | - Aurélia Barascu
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France.,UMR 8226-CNRS/UPMC, Institut de Biologie Physico-chimique, Sorbonne Université, 13 rue Pierre et Marie Curie, F-75005Paris, France
| | - Thierry Moreau
- Université de Tours, F-37032Tours, France.,INRA, UMR INRA 0083 - Biologie des Oiseaux et Aviculture (BOA), F-37380Nouzilly, France
| | - Agnès Petit-Courty
- Université de Tours, F-37032Tours, France.,INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France
| | - Damien Sizaret
- Département d'Anatomie et Cytologie Pathologiques, Hôpital Trousseau, CHRU de Tours, F-37044Tours, France
| | - Yves Courty
- INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France
| | - Sophie Iochmann
- Université de Tours, F-37032Tours, France.,INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France.,Institut Universitaire de Technologie, F-37082Tours, France
| | - Pascale Reverdiau
- Université de Tours, F-37032Tours, France.,INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, 10 boulevard Tonnellé, F-37032Tours, France.,Institut Universitaire de Technologie, F-37082Tours, France
| |
Collapse
|
18
|
Khan T, Kryza T, Lyons NJ, He Y, Hooper JD. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. Cancer Res 2021; 81:2259-2269. [PMID: 33509939 DOI: 10.1158/0008-5472.can-20-2978] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 12/22/2020] [Accepted: 01/22/2021] [Indexed: 11/16/2022]
Abstract
CUB-domain containing protein 1 (CDCP1) is a type I transmembrane glycoprotein that is upregulated in malignancies of the breast, lung, colorectum, ovary, kidney, liver, pancreas, and hematopoietic system. Here, we discuss CDCP1 as an important hub for oncogenic signaling and its key roles in malignant transformation and summarize approaches focused on exploiting it for cancer diagnosis and therapy. Elevated levels of CDCP1 are associated with progressive disease and markedly poorer survival. Predominantly located on the cell surface, CDCP1 lies at the nexus of key tumorigenic and metastatic signaling cascades, including the SRC/PKCδ, PI3K/AKT, WNT, and RAS/ERK axes, the oxidative pentose phosphate pathway, and fatty acid oxidation, making important functional contributions to cancer cell survival and growth, metastasis, and treatment resistance. These findings have stimulated the development of agents that target CDCP1 for detection and treatment of a range of cancers, and results from preclinical models suggest that these approaches could be efficacious and have manageable toxicity profiles.
Collapse
Affiliation(s)
- Tashbib Khan
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Thomas Kryza
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Nicholas J Lyons
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Yaowu He
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - John D Hooper
- Mater Research Institute - The University of Queensland, Translational Research Institute, Woolloongabba, Queensland, Australia.
| |
Collapse
|
19
|
Tse BWC, Kryza T, Yeh MC, Dong Y, Sokolowski KA, Walpole C, Dreyer T, Felber J, Harris J, Magdolen V, Russell PJ, Clements JA. KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. Cancers (Basel) 2020; 12:cancers12123501. [PMID: 33255452 PMCID: PMC7761350 DOI: 10.3390/cancers12123501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 11/19/2020] [Accepted: 11/20/2020] [Indexed: 12/05/2022] Open
Abstract
Simple Summary The serine protease kallikrein-related peptidase 4 (KLK4) has been reported to potentially play a role in the progression of prostate cancer and other cancer types. However, most of these reports have been limited to in vitro studies. In vivo cancer models offer greater complexity to mimic the characteristics of cancer growth and metastasis in humans. In this study, we used in vivo models of prostate cancer and demonstrated that KLK4 can strongly inhibit the growth of primary prostate tumors as well as bone metastases. To our knowledge, this is the first report of an anti-tumor effect of KLK4 in prostate cancer in vivo. Abstract Recent reports have suggested the role of kallikrein-related peptidase 4 (KLK4) to be that of remodeling the tumor microenvironment in many cancers, including prostate cancer. Notably, these studies have suggested a pro-tumorigenic role for KLK4, especially in prostate cancer. However, these have been primarily in vitro studies, with limited in vivo studies performed to date. Herein, we employed an orthotopic inoculation xenograft model to mimic the growth of primary tumors, and an intracardiac injection to induce metastatic dissemination to determine the in vivo tumorigenic effects of KLK4 overexpressed in PC3 prostate cancer cells. Notably, we found that these KLK4-expressing cells gave rise to smaller localized tumors and decreased metastases than the parent PC-3 cells. To our knowledge, this is the first report of an anti-tumorigenic effect of KLK4, particularly in prostate cancer. These findings also provide a cautionary tale of the need for in vivo analyses to substantiate in vitro experimental data.
Collapse
Affiliation(s)
- Brian W.-C. Tse
- Preclinical Imaging Facility, Translational Research Institute, Brisbane 4102, Australia;
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
- Correspondence:
| | - Thomas Kryza
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
- Translational Research Institute, Mater Research Institute—The University of Queensland, Brisbane 4102, Australia
| | - Mei-Chun Yeh
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
| | - Ying Dong
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
| | - Kamil A. Sokolowski
- Preclinical Imaging Facility, Translational Research Institute, Brisbane 4102, Australia;
| | - Carina Walpole
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
- Translational Research Institute, Mater Research Institute—The University of Queensland, Brisbane 4102, Australia
| | - Tobias Dreyer
- Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (T.D.); (J.F.); (V.M.)
| | - Johanna Felber
- Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (T.D.); (J.F.); (V.M.)
| | - Jonathan Harris
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
| | - Viktor Magdolen
- Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, 81675 Munich, Germany; (T.D.); (J.F.); (V.M.)
| | - Pamela J. Russell
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre—Queensland, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane 4102, Australia; (T.K.); (M.-C.Y.); (Y.D.); (C.W.); (P.J.R.); (J.A.C.)
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane 4102, Australia;
| |
Collapse
|
20
|
Khan T, Sullivan MA, Gunter JH, Kryza T, Lyons N, He Y, Hooper JD. Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation. Front Oncol 2020; 10:592455. [PMID: 33224887 PMCID: PMC7667517 DOI: 10.3389/fonc.2020.592455] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Accepted: 09/15/2020] [Indexed: 02/06/2023] Open
Abstract
Once thought to be exclusively a storage hub for glucose, glycogen is now known to be essential in a range of physiological processes and pathological conditions. Glycogen lies at the nexus of diverse processes that promote malignancy, including proliferation, migration, invasion, and chemoresistance of cancer cells. It is also implicated in processes associated with the tumor microenvironment such as immune cell effector function and crosstalk with cancer-associated fibroblasts to promote metastasis. The enzymes of glycogen metabolism are dysregulated in a wide variety of malignancies, including cancers of the kidney, ovary, lung, bladder, liver, blood, and breast. Understanding and targeting glycogen metabolism in cancer presents a promising but under-explored therapeutic avenue. In this review, we summarize the current literature on the role of glycogen in cancer progression and discuss its potential as a therapeutic target for cancer treatment.
Collapse
Affiliation(s)
- Tashbib Khan
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Mitchell A. Sullivan
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Jennifer H. Gunter
- Faculty of Health, Australian Prostate Cancer Research Centre-Queensland, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Woolloongabba, QLD, Australia
| | - Thomas Kryza
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Nicholas Lyons
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Yaowu He
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - John D. Hooper
- Mater Research Institute—The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| |
Collapse
|
21
|
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. Cancers (Basel) 2020; 12:E869. [PMID: 32260077 PMCID: PMC7226162 DOI: 10.3390/cancers12040869] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 03/30/2020] [Accepted: 04/01/2020] [Indexed: 12/19/2022] Open
Abstract
High stage and recurrent ovarian clear cell carcinoma (OCC) are associated with poor prognosis and resistance to chemotherapy. A distinguishing histological feature of OCC is abundant cytoplasmic stores of glucose, in the form of glycogen, that can be mobilized for cellular metabolism. Here, we report the effect on preclinical models of OCC of disrupting glycogen utilization using the glucose analogue 2-deoxy-D-glucose (2DG). At concentrations significantly lower than previously reported for other cancers, 2DG markedly improves the efficacy in vitro of carboplatin chemotherapy against chemo-sensitive TOV21G and chemo-resistant OVTOKO OCC cell lines, and this is accompanied by the depletion of glycogen. Of note, 2DG doses-of more than 10-fold lower than previously reported for other cancers-significantly improve the efficacy of carboplatin against cell line and patient-derived xenograft models in mice that mimic the chemo-responsiveness of OCC. These findings are encouraging, in that 2DG doses, which are substantially lower than previously reported to cause adverse events in cancer patients, can safely and significantly improve the efficacy of carboplatin against OCC. Our results thus justify clinical trials to evaluate whether low dose 2DG improves the efficacy of carboplatin in OCC patients.
Collapse
Affiliation(s)
- Tashbib Khan
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Yaowu He
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Thomas Kryza
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Brittney S. Harrington
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Jennifer H. Gunter
- Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Brisbane, QLD 4102, Australia;
| | - Mitchell A. Sullivan
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Tahleesa Cuda
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Rebecca Rogers
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Claire M. Davies
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Amy Broomfield
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Madeline Gough
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Andy C. Wu
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Thomas McGann
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - S. John Weroha
- Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA; (S.J.W.); (P.H.)
| | - Paul Haluska
- Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA; (S.J.W.); (P.H.)
- Bristol-Myers Squibb, Princeton, NJ 08540, USA
| | - Josephine M. Forbes
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| | - Jane E. Armes
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Sinead C. Barry
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Jermaine I. Coward
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- ICON Cancer Care, South Brisbane, QLD 4101, Australia
| | - Nisha Jagasia
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Naven Chetty
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Cameron E. Snell
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Rohan Lourie
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - Lewis C. Perrin
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
- Mater Brisbane Hospital, Mater Health Services, South Brisbane, QLD 4101, Australia; (A.B.); (M.G.); (N.J.); (N.C.)
| | - John D. Hooper
- Mater Research Institute, The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia; (T.K.); (Y.H.); (T.K.); (B.S.H.); (M.A.S.); (T.C.); (R.R.); (C.M.D.); (A.C.W.); (T.M.); (J.M.F.); (J.E.A.); (S.C.B.); (J.I.C.); (C.E.S.); (R.L.); (L.C.P.)
| |
Collapse
|
22
|
Kryza T, Khan T, Puttick S, Li C, Sokolowski KA, Tse BWC, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics 2020; 10:4116-4133. [PMID: 32226543 PMCID: PMC7086361 DOI: 10.7150/thno.43589] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Accepted: 02/07/2020] [Indexed: 12/12/2022] Open
Abstract
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signalling pathways in malignant cells. CDCP1 has been proposed as a molecular target to abrogate oncogenic signalling pathways and specifically deliver anti-cancer agents to tumors. However, the development of CDCP1-targeting agents has been questioned by its frequent proteolytic processing which was thought to result in shedding of the CDCP1 extracellular domain limiting its targetability. In this study, we investigated the relevance of targeting CDCP1 in the context of pancreatic ductal adenocarcinoma (PDAC) and assess the impact of CDCP1 proteolysis on the effectiveness of CDCP1 targeting agents. Methods: The involvement of CDCP1 in PDAC progression was assessed by association analysis in several PDAC cohorts and the proteolytic processing of CDCP1 was evaluated in PDAC cell lines and patient-derived cells. The consequences of CDCP1 proteolysis on its targetability in PDAC cells was assessed using immunoprecipitation, immunostaining and biochemical assays. The involvement of CDCP1 in PDAC progression was examined by loss-of-function in vitro and in vivo experiments employing PDAC cells expressing intact or cleaved CDCP1. Finally, we generated antibody-based imaging and therapeutic agents targeting CDCP1 to demonstrate the feasibility of targeting this receptor for detection and treatment of PDAC tumors. Results: High CDCP1 expression in PDAC is significantly associated with poorer patient survival. In PDAC cells proteolysis of CDCP1 does not always result in the shedding of CDCP1-extracellular domain which can interact with membrane-bound CDCP1 allowing signal transduction between the different CDCP1-fragments. Targeting CDCP1 impairs PDAC cell functions and PDAC tumor growth independently of CDCP1 cleavage status. A CDCP1-targeting antibody is highly effective at delivering imaging radionuclides and cytotoxins to PDAC cells allowing specific detection of tumors by PET/CT imaging and superior anti-tumor effects compared to gemcitabine in in vivo models. Conclusion: Independent of its cleavage status, CDCP1 exerts oncogenic functions in PDAC and has significant potential to be targeted for improved radiological staging and treatment of this cancer. Its elevated expression by most PDAC tumors and lack of expression by normal pancreas and other major organs, suggest that targeting CDCP1 could benefit a significant proportion of PDAC patients. These data support the further development of CDCP1-targeting agents as personalizable tools for effective imaging and treatment of PDAC.
Collapse
|
23
|
Harrington BS, He Y, Khan T, Puttick S, Conroy PJ, Kryza T, Cuda T, Sokolowski KA, Tse BWC, Robbins KK, Arachchige BJ, Stehbens SJ, Pollock PM, Reed S, Weroha SJ, Haluska P, Salomon C, Lourie R, Perrin LC, Law RHP, Whisstock JC, Hooper JD. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Am J Cancer Res 2020; 10:2095-2114. [PMID: 32104500 PMCID: PMC7019151 DOI: 10.7150/thno.30736] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Accepted: 12/13/2019] [Indexed: 12/12/2022] Open
Abstract
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival in vitro, and tumor growth and metastasis in vivo. Here we characterize two anti-CDCP1 antibodies, focusing on immuno-conjugates of one of these as a tool to detect and inhibit ovarian cancer. Methods: A panel of ovarian cancer cell lines was examined for cell surface expression of CDCP1 and loss of expression induced by anti-CDCP1 antibodies 10D7 and 41-2 using flow cytometry and Western blot analysis. Surface plasmon resonance analysis and examination of truncation mutants was used to analyse the binding properties of the antibodies for CDCP1. Live-cell spinning-disk confocal microscopy of GFP-tagged CDCP1 was used to track internalization and intracellular trafficking of CDCP1/antibody complexes. In vivo, zirconium 89-labelled 10D7 was detected by positron-emission tomography imaging, of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. The efficacy of cytotoxin-conjugated 10D7 was examined against ovarian cancer cells in vitro and in vivo. Results: Our data indicate that each antibody binds with high affinity to the extracellular domain of CDCP1 causing rapid internalization of the receptor/antibody complex and degradation of CDCP1 via processes mediated by the kinase Src. Highlighting the potential clinical utility of CDCP1, positron-emission tomography imaging, using zirconium 89-labelled 10D7, was able to detect subcutaneous and intraperitoneal xenograft ovarian cancers in mice, including small (diameter <3 mm) tumor deposits of an ovarian cancer patient-derived xenograft grown intraperitoneally in mice. Furthermore, cytotoxin-conjugated 10D7 was effective at inhibiting growth of CDCP1-expressing ovarian cancer cells in vitro and in vivo. Conclusions: These data demonstrate that CDCP1 internalizing antibodies have potential for killing and detection of CDCP1 expressing ovarian cancer cells.
Collapse
|
24
|
Kryza T, Bock N, Lovell S, Rockstroh A, Lehman ML, Lesner A, Panchadsaram J, Silva LM, Srinivasan S, Snell CE, Williams ED, Fazli L, Gleave M, Batra J, Nelson C, Tate EW, Harris J, Hooper JD, Clements JA. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. Mol Oncol 2019; 14:105-128. [PMID: 31630475 PMCID: PMC6944120 DOI: 10.1002/1878-0261.12587] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 09/06/2019] [Accepted: 10/18/2019] [Indexed: 12/20/2022] Open
Abstract
Kallikrein-related peptidase 14 (KLK14) is one of the several secreted KLK serine proteases involved in prostate cancer (PCa) pathogenesis. While relatively understudied, recent reports have identified KLK14 as overexpressed during PCa development. However, the modulation of KLK14 expression during PCa progression and the molecular and biological functions of this protease in the prostate tumor microenvironment remain unknown. To determine the modulation of KLK14 expression during PCa progression, we analyzed the expression levels of KLK14 in patient samples using publicly available databases and immunohistochemistry. In order to delineate the molecular mechanisms involving KLK14 in PCa progression, we integrated proteomic, transcriptomic, and in vitro assays with the goal to identify substrates, related-signaling pathways, and functional roles of this protease. We showed that KLK14 expression is elevated in advanced PCa, and particularly in metastasis. Additionally, KLK14 levels were found to be decreased in PCa tissues from patients responsive to neoadjuvant therapy compared to untreated patients. Furthermore, we also identified that KLK14 expression reoccurred in patients who developed castrate-resistant PCa. The combination of proteomic and transcriptomic analysis as well as functional assays revealed several new KLK14 substrates (agrin, desmoglein 2, vitronectin, laminins) and KLK14-regulated genes (Interleukin 32, midkine, SRY-Box 9), particularly an involvement of the mitogen-activated protein kinase 1 and interleukin 1 receptor pathways, and an involvement of KLK14 in the regulation of cellular migration, supporting its involvement in aggressive features of PCa progression. In conclusion, our work showed that KLK14 expression is associated with the development of aggressive PCa suggesting that targeting this protease could offer a novel route to limit the progression of prostate tumors. Additional work is necessary to determine the benefits and implications of targeting/cotargeting KLK14 in PCa as well as to determine the potential use of KLK14 expression as a predictor of PCa aggressiveness or response to treatment.
Collapse
Affiliation(s)
- Thomas Kryza
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia.,Mater Research Institute - The University of Queensland, Brisbane, Australia
| | - Nathalie Bock
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Scott Lovell
- Department of Chemistry, Imperial College London, UK
| | - Anja Rockstroh
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Melanie L Lehman
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia.,Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Canada
| | - Adam Lesner
- Faculty of Chemistry, University of Gdansk, Poland
| | - Janaththani Panchadsaram
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Lakmali Munasinghage Silva
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Srilakshmi Srinivasan
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Cameron E Snell
- Mater Research Institute - The University of Queensland, Brisbane, Australia.,Mater Health Services, South Brisbane, Australia
| | - Elizabeth D Williams
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Ladan Fazli
- Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Canada
| | - Martin Gleave
- Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Canada
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Colleen Nelson
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| | - Edward W Tate
- Department of Chemistry, Imperial College London, UK
| | - Jonathan Harris
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia
| | - John D Hooper
- Mater Research Institute - The University of Queensland, Brisbane, Australia.,Mater Health Services, South Brisbane, Australia
| | - Judith A Clements
- Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Institute of Health & Biomedical Innovation, Queensland University of Technology, Woolloongabba, Australia.,School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Woolloongabba, Australia.,Translational Research Institute, Woolloongabba, Australia
| |
Collapse
|
25
|
Bock N, Shokoohmand A, Kryza T, Röhl J, Meijer J, Tran PA, Nelson CC, Clements JA, Hutmacher DW. Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment. Bone Res 2019; 7:13. [PMID: 31044095 PMCID: PMC6486620 DOI: 10.1038/s41413-019-0049-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 02/13/2019] [Accepted: 03/04/2019] [Indexed: 02/06/2023] Open
Abstract
While stromal interactions are essential in cancer adaptation to hormonal therapies, the effects of bone stroma and androgen deprivation on cancer progression in bone are poorly understood. Here, we tissue-engineered and validated an in vitro microtissue model of osteoblastic bone metastases, and used it to study the effects of androgen deprivation in this microenvironment. The model was established by culturing primary human osteoprogenitor cells on melt electrowritten polymer scaffolds, leading to a mineralized osteoblast-derived microtissue containing, in a 3D setting, viable osteoblastic cells, osteocytic cells, and appropriate expression of osteoblast/osteocyte-derived mRNA and proteins, and mineral content. Direct co-culture of androgen receptor-dependent/independent cell lines (LNCaP, C4-2B, and PC3) led cancer cells to display functional and molecular features as observed in vivo. Co-cultured cancer cells showed increased affinity to the microtissues, as a function of their bone metastatic potential. Co-cultures led to alkaline phosphatase and collagen-I upregulation and sclerostin downregulation, consistent with the clinical marker profile of osteoblastic bone metastases. LNCaP showed a significant adaptive response under androgen deprivation in the microtissues, with the notable appearance of neuroendocrine transdifferentiation features and increased expression of related markers (dopa decarboxylase, enolase 2). Androgen deprivation affected the biology of the metastatic microenvironment with stronger upregulation of androgen receptor, alkaline phosphatase, and dopa decarboxylase, as seen in the transition towards resistance. The unique microtissues engineered here represent a substantial asset to determine the involvement of the human bone microenvironment in prostate cancer progression and response to a therapeutic context in this microenvironment.
Collapse
Affiliation(s)
- Nathalie Bock
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
- Centre in Regenerative Medicine, QUT, Kelvin Grove, QLD 4059 Australia
| | - Ali Shokoohmand
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
- Centre in Regenerative Medicine, QUT, Kelvin Grove, QLD 4059 Australia
| | - Thomas Kryza
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
| | - Joan Röhl
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
| | - Jonelle Meijer
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
- Centre in Regenerative Medicine, QUT, Kelvin Grove, QLD 4059 Australia
| | - Phong A. Tran
- Centre in Regenerative Medicine, QUT, Kelvin Grove, QLD 4059 Australia
- Bone and Joint Disorders Program, School of Chemistry, Physics and Mechanical Engineering, Science and Engineering Faculty (SEF), QUT, Brisbane, QLD 4000 Australia
| | - Colleen C. Nelson
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
| | - Judith A. Clements
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
| | - Dietmar W. Hutmacher
- School of Biomedical Sciences, Faculty of Health and Australian Prostate Cancer Research Centre (APCRC-Q), Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD 4000 Australia
- Translational Research Institute (TRI), Woolloongabba, QLD 4102 Australia
- Centre in Regenerative Medicine, QUT, Kelvin Grove, QLD 4059 Australia
- Bone and Joint Disorders Program, School of Chemistry, Physics and Mechanical Engineering, Science and Engineering Faculty (SEF), QUT, Brisbane, QLD 4000 Australia
- Australian Research Council (ARC) Training Centre in Additive Biomanufacturing, QUT, Kelvin Grove, QLD 4059 Australia
| |
Collapse
|
26
|
Silva LM, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens CR, Hastie ML, Magdolen V, Kleifeld O, Gorman JJ, Clements JA. Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Mol Cell Proteomics 2019; 18:818-836. [PMID: 30705123 DOI: 10.1074/mcp.ra118.001304] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Indexed: 12/31/2022] Open
Abstract
Kallikrein-related peptidase 7 (KLK7) is a serine peptidase that is over expressed in ovarian cancer. In vitro functional analyses have suggested KLK7 to play a cancer progressive role, although monitoring of KLK7 expression has suggested a contradictory protective role for KLK7 in ovarian cancer patients. In order to help delineate its mechanism of action and thereby the functional roles, information on its substrate repertoire is crucial. Therefore, in this study a quantitative proteomics approach-PROtein TOpography and Migration Analysis Platform (PROTOMAP)-coupled with SILAC was used for in-depth analysis of putative KLK7 substrates from a representative ovarian cancer cell line, SKOV-3, secreted proteins. The Terminal Amine Isotopic Labeling of Substrates (TAILS) approach was used to determine the exact cleavage sites and to validate qPROTOMAP-identified putative substrates. By employing these two technically divergent approaches, exact cleavage sites on 16 novel putative substrates and two established substrates, matrix metalloprotease (MMP) 2 and insulin growth factor binding protein 3 (IGFBP3), were identified in the SKOV-3 secretome. Eight of these substrates were also identified on TAILS analysis of another ovarian cancer cell (OVMZ-6) secretome, with a further seven OVMZ-6 substrates common to the SKOV-3 qPROTOMAP profile. Identified substrates were significantly associated with the common processes of cell adhesion, extracellular matrix remodeling and cell migration according to the gene ontology (GO) biological process analysis. Biochemical validation supports a role for KLK7 in directly activating pro-MMP10, hydrolysis of IGFBP6 and cleavage of thrombospondin 1 with generation of a potentially bioactive N-terminal fragment. Overall, this study constitutes the most comprehensive analysis of the putative KLK7 degradome in any cancer to date, thereby opening new avenues for KLK7 research.
Collapse
Affiliation(s)
- Lakmali Munasinghage Silva
- From the ‡Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia;; ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany.
| | - Thomas Kryza
- From the ‡Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia;; ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany
| | - Thomas Stoll
- §Protein Discovery Centre, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Christine Hoogland
- §Protein Discovery Centre, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia;; ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany
| | - Ying Dong
- From the ‡Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia
| | - Carson Ryan Stephens
- From the ‡Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia;; ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany
| | - Marcus Lachlan Hastie
- §Protein Discovery Centre, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Viktor Magdolen
- ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany
| | - Oded Kleifeld
- ¶Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Victoria, Australia 3800;; ‖Klinische Forschergruppe der Frauenklinik, Klinikum Rechts der Isar, TU München, Munich, Germany
| | - Jeffrey John Gorman
- §Protein Discovery Centre, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Judith Ann Clements
- From the ‡Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia;.
| |
Collapse
|
27
|
Abstract
Genome-wide association studies (GWAS) have been successful in deciphering the genetic component of predisposition to many human complex diseases including prostate cancer. Germline variants identified by GWAS progressively unravelled the substantial knowledge gap concerning prostate cancer heritability. With the beginning of the post-GWAS era, more and more studies reveal that, in addition to their value as risk markers, germline variants can exert active roles in prostate oncogenesis. Consequently, current research efforts focus on exploring the biological mechanisms underlying specific susceptibility loci known as causal variants by applying novel and precise analytical methods to available GWAS data. Results obtained from these post-GWAS analyses have highlighted the potential of exploiting prostate cancer risk-associated germline variants to identify new gene networks and signalling pathways involved in prostate tumorigenesis. In this Review, we describe the molecular basis of several important prostate cancer-causal variants with an emphasis on using post-GWAS analysis to gain insight into cancer aetiology. In addition to discussing the current status of post-GWAS studies, we also summarize the main molecular mechanisms of potential causal variants at prostate cancer risk loci and explore the major challenges in moving from association to functional studies and their implication in clinical translation.
Collapse
Affiliation(s)
- Samaneh Farashi
- Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
- Australian Prostate Cancer Research Centre - Queensland, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Thomas Kryza
- Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
- Australian Prostate Cancer Research Centre - Queensland, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Judith Clements
- Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
- Australian Prostate Cancer Research Centre - Queensland, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland, Australia
| | - Jyotsna Batra
- Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
- Australian Prostate Cancer Research Centre - Queensland, Queensland University of Technology, Translational Research Institute, Woolloongabba, Queensland, Australia.
| |
Collapse
|
28
|
Kryza T, Parent C, Pardessus J, Petit A, Burlaud-Gaillard J, Reverdiau P, Iochmann S, Labas V, Courty Y, Heuzé-Vourc'h N. Human kallikrein-related peptidase 12 stimulates endothelial cell migration by remodeling the fibronectin matrix. Sci Rep 2018; 8:6331. [PMID: 29679011 PMCID: PMC5910384 DOI: 10.1038/s41598-018-24576-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 04/05/2018] [Indexed: 12/30/2022] Open
Abstract
Kallikrein-related peptidase 12 (KLK12) is a kallikrein family peptidase involved in angiogenesis - a complex biological process in which the sprouting, migration and stabilization of endothelial cells requires extracellular matrix remodeling. To characterize the molecular mechanisms associated with KLK12's proangiogenic activity, we evaluated its ability to hydrolyze various matrix proteins. Our results show that KLK12 efficiently cleaved the human extracellular matrix proteins fibronectin and tenascin, both of which are involved in the regulation of endothelial cell adhesion and migration. For fibronectin, the major proteolytic product generated by KLK12 was a 29 kDa fragment containing the amino-terminal domain and the first five type I fibronectin-domains, which are essential for regulating fibronectin assembly. We also demonstrated that KLK12-mediated fibronectin proteolysis antagonizes fibronectin polymerization and fibronectin fibril formation by endothelial cells, leading to an increase in cell migration. Furthermore, a polyclonal antibody raised against KLK12's proteolytic cleavage site on fibronectin prevented the KLK12-dependent inhibition of fibronectin polymerization and the KLK12-mediated pro-migratory effect on endothelial cells. Taken as a whole, our results indicate that KLK12's proangiogenic effect is mediated through several molecular mechanisms.
Collapse
Affiliation(s)
- T Kryza
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France.,Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Australia
| | - C Parent
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - J Pardessus
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - A Petit
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - J Burlaud-Gaillard
- Université François Rabelais de Tours, F-37032, Tours, France.,Plateforme IBiSA de Microscopie Electronique, Université François Rabelais de Tours, F-37032, Tours, France
| | - P Reverdiau
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - S Iochmann
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - V Labas
- PRC, INRA, CNRS, Université François Rabelais de Tours, IFCE, F-37380, Nouzilly, France.,PAIB, CIRE, INRA, CHRU de Tours, Université François Rabelais de Tours, F-37380, Nouzilly, France
| | - Y Courty
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France.,Université François Rabelais de Tours, F-37032, Tours, France
| | - N Heuzé-Vourc'h
- INSERM, Centre d'Etude des Pathologies Respiratoires, U1100, F-37032, Tours, France. .,Université François Rabelais de Tours, F-37032, Tours, France.
| |
Collapse
|
29
|
Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA. Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells. Mol Oncol 2017; 11:1307-1329. [PMID: 28510269 PMCID: PMC5623815 DOI: 10.1002/1878-0261.12075] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Revised: 04/11/2017] [Accepted: 04/27/2017] [Indexed: 01/09/2023] Open
Abstract
The reciprocal communication between cancer cells and their microenvironment is critical in cancer progression. Although involvement of cancer‐associated fibroblasts (CAF) in cancer progression is long established, the molecular mechanisms leading to differentiation of CAFs from normal fibroblasts are poorly understood. Here, we report that kallikrein‐related peptidase‐4 (KLK4) promotes CAF differentiation. KLK4 is highly expressed in prostate epithelial cells of premalignant (prostatic intraepithelial neoplasia) and malignant lesions compared to normal prostate epithelia, especially at the peristromal interface. KLK4 induced CAF‐like features in the prostate‐derived WPMY1 normal stromal cell line, including increased expression of alpha‐smooth muscle actin, ESR1 and SFRP1. KLK4 activated protease‐activated receptor‐1 in WPMY1 cells increasing expression of several factors (FGF1, TAGLN, LOX, IL8, VEGFA) involved in prostate cancer progression. In addition, KLK4 induced WPMY1 cell proliferation and secretome changes, which in turn stimulated HUVEC cell proliferation that could be blocked by a VEGFA antibody. Importantly, the genes dysregulated by KLK4 treatment of WPMY1 cells were also differentially expressed between patient‐derived CAFs compared to matched nonmalignant fibroblasts and were further increased by KLK4 treatment. Taken together, we propose that epithelial‐derived KLK4 promotes tumour progression by actively promoting CAF differentiation in the prostate stromal microenvironment.
Collapse
Affiliation(s)
- Thomas Kryza
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology (QUT), Woolloongabba, Australia.,Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Lakmali M Silva
- Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Nathalie Bock
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology (QUT), Woolloongabba, Australia.,Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Ruth A Fuhrman-Luck
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology (QUT), Woolloongabba, Australia.,Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Carson R Stephens
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology (QUT), Woolloongabba, Australia.,Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Jin Gao
- Regenerative Dentistry and Oral Biology, Oral Health Centre, University of Queensland, Herston, Australia
| | - Hema Samaratunga
- Aquesta Pathology, Toowong, Australia.,School of Medicine, University of Queensland, Herston, Australia
| | -
- Australian Prostate Cancer BioResource, The Prostate Cancer Research Program, Monash University, Clayton, Australia
| | - Mitchell G Lawrence
- Prostate Research Group, Cancer Program - Biomedicine Discovery Institute Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium, Monash University, Clayton, Australia
| | - John D Hooper
- Cancer Biology and Care Program, Translational Research Institute, Mater Research Institute - The University of Queensland, Woolloongabba, Australia
| | - Ying Dong
- Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| | - Gail P Risbridger
- Prostate Research Group, Cancer Program - Biomedicine Discovery Institute Department of Anatomy and Developmental Biology, Monash Partners Comprehensive Cancer Consortium, Monash University, Clayton, Australia.,Prostate Cancer Translational Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Parkville, Australia.,Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - Judith A Clements
- Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology (QUT), Woolloongabba, Australia.,Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology (QUT), Kelvin Grove, Australia
| |
Collapse
|
30
|
Silva LM, Stoll T, Kryza T, Stephens CR, Hastie ML, Irving-Rodgers HF, Dong Y, Gorman JJ, Clements JA. Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency. Sci Rep 2017; 7:6789. [PMID: 28754951 PMCID: PMC5533777 DOI: 10.1038/s41598-017-06680-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 06/15/2017] [Indexed: 11/23/2022] Open
Abstract
The cleavage preferences of Kallikrein-related peptidase 7 (KLK7) have previously been delineated using synthetic peptide libraries of fixed length, or single protein chains and have suggested that KLK7 exerts a chymotryptic-like cleavage preference. Due to the short length of the peptides utilised, only a limited number of subsites have however been assessed. To determine the subsite preferences of KLK7 in a global setting, we used a mass spectrometry (MS)-based in-depth proteomics approach that utilises human proteome-derived peptide libraries of varying length, termed Proteomic Identification of protease Cleavage Sites (PICS). Consistent with previous findings, KLK7 was found to exert chymotryptic-like cleavage preferences. KLK7 subsite preferences were also characterised in the P2-P2′ region, demonstrating a preference for hydrophobic residues in the non-prime and hydrophilic residues in the prime subsites. Interestingly, single catalytic triad mutant KLK7 (mKLK7; S195A) also showed residual catalytic activity (kcat/KM = 7.93 × 102 s−1M−1). Catalytic inactivity of KLK7 was however achieved by additional mutation in this region (D102N). In addition to characterising the cleavage preferences of KLK7, our data thereby also suggests that the use of double catalytic triad mutants should be employed as more appropriate negative controls in future investigations of KLK7, especially when highly sensitive MS-based approaches are employed.
Collapse
Affiliation(s)
- Lakmali Munasinghage Silva
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.,Proteases and Tissue Remodelling Section, National Institute of Dental and Craniofacial Research, National Institutes of Science, 30 Convent Drive, Bethesda, Maryland, 20892, USA
| | - Thomas Stoll
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Thomas Kryza
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia
| | - Carson Ryan Stephens
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia
| | - Marcus Lachlan Hastie
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Helen Frances Irving-Rodgers
- School of Medical Science, Griffith University Gold Coast Campus, Parklands Drive, Southport, Queensland, 4215, Australia
| | - Ying Dong
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia
| | - Jeffrey John Gorman
- QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland, 4006, Australia
| | - Judith Ann Clements
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI) and School of Biomedical Sciences at the Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
| |
Collapse
|
31
|
Kryza T, Achard C, Parent C, Marchand-Adam S, Guillon-Munos A, Iochmann S, Korkmaz B, Respaud R, Courty Y, Heuze-Vourc’h N. L’effet proangiogénique de KLK12 est dépendant de la biodisponiblité du Platelet-derived growth factor-B (PDGF-B). Rev Mal Respir 2014. [DOI: 10.1016/j.rmr.2014.04.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Kryza T, Achard C, Parent C, Marchand-Adam S, Guillon-Munos A, Iochmann S, Korkmaz B, Respaud R, Courty Y, Heuzé-Vourc'h N. Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway. FASEB J 2013; 28:740-51. [PMID: 24225148 DOI: 10.1096/fj.13-237503] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
KLK12, a kallikrein peptidase, is thought to take part in the control of angiogenesis. Our analysis of the secretome of endothelial cells (ECs) that had been treated with KLK12 showed that KLK12 converts the extracellular matrix- or membrane-bound precursor of platelet-derived growth factor B (PDGF-B) into a soluble form. Both PDGF-B and vascular endothelial growth factor A (VEGF-A) take part in the induction of angiogenesis by KLK12 in a coculture model of angiogenesis that mimics endothelial tubule formation. We used a cellular approach to analyze the interplay between KLK12, PDGF-B, and VEGF-A and showed that release of PDGF-B by KLK12 leads to the fibroblast-mediated secretion of VEGF-A. This then stimulates EC differentiation and the formation of capillary tube-like structures. Thus, KLK12 favors the interaction of ECs and stromal cells. The released PDGF-B acts as a paracrine factor that modulates VEGF-A secretion by stromal cells, which ultimately leads to angiogenesis. Moreover, the genes encoding KLK12 and PDGFB are both expressed in ECs and up-regulated in tumor cells kept under hypoxic conditions, which is consistent with the physiological involvement of KLK12 in PDGF-B maturation.
Collapse
Affiliation(s)
- Thomas Kryza
- 2CEPR INSERM U1100/EA 6305, Faculté de Médecine, 10 Blvd. Tonnellé, F-37032 Tours cedex, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Brellier F, Martina E, Degen M, Heuzé-Vourc'h N, Petit A, Kryza T, Courty Y, Terracciano L, Ruiz C, Chiquet-Ehrismann R. Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors. BMC Clin Pathol 2012; 12:14. [PMID: 22947174 PMCID: PMC3444373 DOI: 10.1186/1472-6890-12-14] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2012] [Accepted: 08/27/2012] [Indexed: 12/20/2022] Open
Abstract
Background Tenascins are large glycoproteins found in the extracellular matrix of many embryonic and adult tissues. Tenascin-C is a well-studied biomarker known for its high overexpression in the stroma of most solid cancers. Tenascin-W, the least studied member of the family, is highly expressed in the stroma of colon and breast tumors and in gliomas, but not in the corresponding normal tissues. Other solid tumors have not been analyzed. The present study was undertaken to determine whether tenascin-W could serve as a cancer-specific extracellular matrix protein in a broad range of solid tumors. Methods We analyzed the expression of tenascin-W and tenascin-C by immunoblotting and by immunohistochemistry on multiple frozen tissue microarrays of carcinomas of the pancreas, kidney and lung as well as melanomas and compared them to healthy tissues. Results From all healthy adult organs tested, only liver and spleen showed detectable levels of tenascin-W, suggesting that tenascin-W is absent from most human adult organs under normal, non-pathological conditions. In contrast, tenascin-W was detectable in the majority of melanomas and their metastases, as well as in pancreas, kidney, and lung carcinomas. Comparing lung tumor samples and matching control tissues for each patient revealed a clear overexpression of tenascin-W in tumor tissues. Although the number of samples examined is too small to draw statistically significant conclusions, there seems to be a tendency for increased tenascin-W expression in higher grade tumors. Interestingly, in most tumor types, tenascin-W is also expressed in close proximity to blood vessels, as shown by CD31 co-staining of the samples. Conclusions The present study extends the tumor biomarker potential of tenascin-W to a broad range of solid tumors and shows its accessibility from the blood stream for potential therapeutic strategies.
Collapse
Affiliation(s)
- Florence Brellier
- Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland
| | - Enrico Martina
- Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland.,Faculty of Sciences, University of Basel, Basel, Switzerland.,Present address: Department of Dermatology, Brigham and Women's Hospital, Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA, USA
| | - Martin Degen
- Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland.,Faculty of Sciences, University of Basel, Basel, Switzerland.,Present address: Department of Dermatology, Brigham and Women's Hospital, Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA, USA
| | - Nathalie Heuzé-Vourc'h
- Université François Rabelais, EA 6305, F-37032, Tours, France.,Centre d'Etude des Pathologies Respiratoires, UMR 1100/EA6305, F-37032, Tours, France
| | - Agnès Petit
- Centre d'Etude des Pathologies Respiratoires, UMR 1100/EA6305, F-37032, Tours, France
| | - Thomas Kryza
- Université François Rabelais, EA 6305, F-37032, Tours, France.,Centre d'Etude des Pathologies Respiratoires, UMR 1100/EA6305, F-37032, Tours, France
| | - Yves Courty
- Centre d'Etude des Pathologies Respiratoires, UMR 1100/EA6305, F-37032, Tours, France
| | - Luigi Terracciano
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - Christian Ruiz
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - Ruth Chiquet-Ehrismann
- Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland.,Faculty of Sciences, University of Basel, Basel, Switzerland
| |
Collapse
|